



Amvi
Biotech Incorporation.

AMERICAN VIETNAMESE BIOTECH INC

ANNUAL REPORT 2025

TRADE NAME:

AMERICAN VIETNAMESE
BIOTECH INC

TRADING CODE:

AMV

Address: 4th Floor, Phu Ma Duong
Building, 85 Hoang Van Thai Street, Tan
My Ward, Ho Chi Minh City

Hotline:

0243 215 1114



Amvi
Biotech Incorporation.

WEBSITE

www.amvibiotech.com

TOTAL
EQUITY

1311

billion VND
(one thousand three
hundred and eleven billion
Vietnamese Dong)

LISTED ON: HNX

First trading day: December 30,
2009

MESSAGE FROM THE COMPANY



American Vietnamese Biotech Inc always takes the mission "For public health - For a sustainable healthcare system" as its guiding principle. We are committed to providing high-quality medical products and services that meet the standards of healthcare facilities with professionalism, transparency, and responsibility, contributing to improving the quality of healthcare in Vietnam.

VISION & MISSION

VISION:

To become a leading enterprise in the distribution of medical equipment, supplies, chemicals, and services.

Continuously expanding the market and business areas to seize new opportunities and prospects..

MISSION

AMV is committed to providing customers and partners with the best products and services.

Sustainable development, with responsibility towards the environment and society.





NHỮNG DẤU MỐC LỊCH SỬ

Ngày đầu
thành lập với
số vốn điều lệ
ban đầu là 15
tỷ đồng

2002

2006

Công ty thực
hiện tăng vốn
điều lệ từ 15 tỷ
đồng lên
15,090 tỷ đồng

Công ty tiến
hành phát
hành cổ phiếu
theo hình thức
phát hành
riêng lẻ cho
Ban Giám đốc
Công ty,
CBNV tăng
vốn điều lệ của
Công ty từ
15,090 tỷ đồng
lên 21 tỷ đồng

2007

2009

Ngày
30/12/2009,
Công ty chính
thức niêm yết
tại Trung tâm
giao dịch
chứng khoán
Hà Nội (nay là
Sở giao dịch
chứng khoán
Hà Nội) với mã
chứng khoán
AMV ..

Công ty là đơn
vị đầu tiên trong
nước sản xuất
que test HIV

1&2. Ngày
7/7/2011 Công
ty khai trương
cơ sở sản xuất
tại xã Tiến
Thành, thị xã
Đồng Xoài, tỉnh
Bình Phước

2011

2017

Công ty phát
hành riêng lẻ cho
cổ đông chiến
lược tăng vốn lên
271.157.500.000
đồng

Công ty phát
hành cổ phiếu để
trả cổ tức, nâng
vốn điều lệ lên
379.620.450.000
đồng.

2020

Công ty phát
hành cổ phiếu để
trả cổ tức, nâng
vốn điều lệ lên
531.468.160.000
đồng.

Công ty phát
hành cổ
phiếu cho cổ
đồng hiện
hữu, nâng
vốn điều lệ
lên
1.311.056.50
0.000
đồng.

2019

2022



ACHIEVEMENTS

With over 20 years of development in the pharmaceutical and medical equipment sector, we have established ourselves as a leading enterprise in Vietnam's healthcare industry.

We are the exclusive distributor of medical testing equipment and biological products from TOSOH, Furuno, Mizuho, Seiko (Japan), and many other international corporations.

We have successfully implemented TRC molecular biology testing systems, IVF systems using Japanese technology, and HIS, LIS, PACS, and RIS medical software in numerous hospitals and clinics.

We have developed a network of 17 subsidiaries and over 100 high-tech clinics nationwide, contributing to the expansion of the community healthcare system.

We have a strategic international partnership with Kato Hospital (Japan) in the transfer of advanced assisted reproductive technology (IVF).

We continuously expand investment and promote the socialization of healthcare, improving the quality of medical examination and treatment and the patient experience in Vietnam.

MIZUHO MEDICAL Co., Ltd.



BUSINESS AREA

AMV aims to become the leading healthcare group in Vietnam and Southeast Asia. Its mission is to bring advanced medical technology closer to the Vietnamese people, improving the quality of life and community health. Core values: Quality – Efficiency – Trust.

F

DISTRIBUTION AND INVESTMENT IN MEDICAL EQUIPMENT AND BIOLOGICAL PRODUCTS

AMV is the official distributor of many leading global medical brands such as Tosoh, Furuno, Seiko, Mizuho, Codonics, Centronic... The company provides a complete range of medical equipment for hospitals, medical centers, and clinics nationwide — from diagnostic imaging, laboratory testing, endoscopy, cancer treatment, obstetrics and pediatrics, surgery, to resuscitation equipment...; AMV's particular strength lies in its modern specialized laboratory equipment, chemical sources, and consumables meeting G7 standards...

A

INVESTING IN CLINIC AND LABORATORY CENTER CHAINS

AMV is a pioneer in the healthcare socialization model, investing in a chain of high-tech clinics specializing in laboratory testing (Golab, Medicare) and a chain of family doctor centers (Famicare) in provinces and cities nationwide. This system is equipped with equipment meeting Japanese, American, and EU standards, providing in-depth testing services, early disease diagnosis, and effective treatment support.

S

DEVELOPMENT OF INFORMATION TECHNOLOGY AND MEDICAL SOFTWARE

AMV focuses on the digital transformation of the healthcare industry, providing HIS, LIS, PACS, and RIS/Alma solutions to help hospitals operate efficiently, standardize data, and make accurate diagnoses.

T

INFERTILITY TREATMENT USING IVF METHOD

The company has been providing a stable IVF assisted reproductive system at Phu Tho Provincial Obstetrics and Pediatrics Hospital and has achieved remarkable results. It began generating profits in 2024. In addition, the company plans to establish AMV-affiliated IVF centers in major cities such as Hanoi, Ho Chi Minh City, Quang Ninh, etc.

+ Investing in complete equipment packages for hospitals. + Investing in a chain of clinics, testing centers , and infusion centers.

This is the company's traditional business segment in the field of supplying hospital equipment. The company aims to provide complete packages (approximately 350 pieces of equipment) that can participate in bidding and ensure quality, cost, and reliable suppliers. Currently, the company is one of the major suppliers for several hospitals.

- ☐ Some medical equipment the company currently supplies includes:
- ☐ Diagnostic imaging equipment
- ☐ Cancer treatment equipment
- ☐ Endoscopy equipment
- ☐ Surgical equipment
- ☐ ENT equipment
- ☐ Obstetrics and pediatrics equipment
- ☐ Nephrology equipment
- ☐ Dentistry equipment
- ☐ Functional diagnostic equipment

AMV aims to become a leading provider of medical equipment in Vietnam and Southeast Asia, specializing in high-tech medical machinery and equipment, investing in a well-established nationwide network of testing centers, etc.

We strive to create advanced medical solutions that improve the quality of healthcare and bring better lives to the community.

We aim to improve people's lives and health by preventing disease through the provision of reliable diagnostic tests at the most cost-effective prices.

- We enhance our modern testing equipment, meeting Japanese standards, to improve the quality of healthcare services, enhance public health, and improve the patient experience.
- Using modern equipment ensures the accuracy and reliability of test results, thereby supporting more effective diagnosis and treatment.
- Provides the capability to perform a wide range of tests, from basic to advanced, meeting the diverse needs of patients in the area and neighboring provinces.



❖ BUSINESS AREA

Leveraging its existing strengths, the company is currently expanding its investment and operations across provinces and cities nationwide, notably Hanoi, Ho Chi Minh City, Phu Tho, Quang Ninh, Hau Giang, Can Tho, Soc Trang, Bac Ninh, Hai Phong, etc.

In 2024 and 2025, the company will continue to manage and maintain operations at its factories in industrial parks, and existing centers and clinics in several provinces, while expanding its business activities to a chain of specialized clinics across regions from north to south. The company expects to gradually bring these clinics and centers to operate effectively, meeting the needs of a large number of people...

AMV aims to become a leading provider of medical equipment in Vietnam and Southeast Asia, specializing in high-tech medical machinery and equipment, investing in a well-established nationwide network of testing centers, and more. We strive to create advanced medical solutions that improve healthcare quality and bring better lives to the community.

We aim to enhance people's lives and health by preventing disease through the provision of reliable diagnostic tests at the most cost-effective prices.






Information technology – medical software

➤ Advanced software product for diagnostic imaging and interpretation of pathology results. RIS

Alma – a Spanish-based advanced diagnostic imaging software. This software offers advanced image analysis features for diagnostic imaging physicians.

- Laboratory management system product – LIS

In early 2017, the company officially acquired the license for the laboratory management system from Sword System of Japan. This is a laboratory management software that has been developed and is widely used in... In Japan, customers highly appreciate the system's stability and accuracy. The system can also manage testing in a centralized manner. (Labcenter)



Information technology medical software cell

Some of the IT and healthcare software solutions the company is currently providing include: **Hospital Management System (HIS) products.**

The company has acquired the license for hospital management software from Japan, which is widely used in Japan, offering high data standardization and synchronization, and enabling the system to operate efficiently. stable determined.

Medical image storage and transmission system - PACS

Previously, X-rays, MRI scans, and CT scans involved developing film in a darkroom and then drying it. The second generation is digital, meaning the film is taken and printed (called laser film or dry film). For this field, the Ministry of Health has a future plan to eliminate film printing in all hospitals. Accordingly, the company will focus on the trend of transitioning from on-site laser film printing to a system that eliminates the need for film printing, instead using laser film. system system save storage and transmission image image y cell

- PACS. To date, the company has implemented a number of hospitals and medical centers that do not print films. The company expects... will To be one in 3 But 4 labour ty occupy Large market share in the PACS sector .

General contractor for projects/retail business of medical equipment

The company is currently aiming to become a general contractor for medical equipment projects. In 2018, AMV was approved by the three largest global testing equipment manufacturers to be the general distributor of their products in Vietnam. This is a new field, expected to help the company reach new heights and achieve good sales. AMV's core business remains the testing sector, including some tests not yet developed in Vietnam such as allergy testing and early cancer diagnosis (stages 0-4)... Currently, the company is actively expanding its market, supplying testing equipment to medical centers, hospitals, and specialized clinics.

The medical equipment the company currently supplies includes:



Automated molecular biological tuberculosis testing system TRC, Tosoh, Japan

This is a molecular biological testing method based on RNA amplification in cells.

****Speed:**** Highest compared to other methods: 8 patient samples processed in 40 minutes -> 5 minutes per patient.

****Sensitivity:**** 98%.

****Specificity:**** 98%.

****Sample types:**** Blood, sputum, stool, urine, fluids, etc. Currently, the company has implemented this method at the National Lung Hospital, Hanoi Lung Hospital, Hau Giang Lung Hospital, Dong Thap Lung Hospital, Phu Tho Provincial General Hospital, Hai Phong International Hospital, etc., and has received many positive feedbacks from users.

Automated immunoassay analyzers from Tosoh, Japan with models: AIA 360, AIA 900, AIA 2000

The advantages of automated immunoassay analyzers are:

- o Fastest results currently available.
- High sensitivity and accuracy of test results;
- fluorescence measurement method reduces interference.

Dry reagents, individually packaged (for each test), making them convenient and economical to use.

Performs 56 comprehensive immunoassay tests.




Infertility treatment center using IVF method

IVF (In vitro fertilization) is a technique for treating infertility in which the husband's sperm and the wife's egg are fertilized in a laboratory to create an embryo.

With Japanese IVF technology, the company has partnered with Kato Hospital, aiming for a superior success rate. This approach, linked to natural mechanisms, minimizes costs and reduces the risk of dangerous side effects and complications. Kato Hospital is a leading IVF hospital in Japan, utilizing proprietary technology called "Minimized Stimulation Technology," which has helped 35,000 babies be born. Beyond Japan, the hospital has developed an international network including IVF centers in the US, China, the Philippines, and now Vietnam. AMV is proud to have successfully met numerous stringent review criteria and high standards set by its partner to become a technology transfer and operational partner in Vietnam.

Currently, the company has been providing a stable IVF assisted reproductive system at Phu Tho Provincial Obstetrics and Pediatrics Hospital and has achieved remarkable results. It is expected to start generating profits in 2024. In addition, the company plans to establish AMV-affiliated IVF centers in major cities such as Hanoi, Ho Chi Minh City, Quang Ninh, etc.



1. INFORMATION ON THE GOVERNANCE MODEL , BUSINESS ORGANIZATION , AND MANAGEMENT

1. Cơ cấu tổ chức Công ty

STRUCTURE QT

As of December 31, 2025, the Company has 13 directly owned subsidiaries and 14 indirectly owned subsidiaries, including:

Company	Place of establishment and operation	Benefit rate	Main business activities
Companies that directly own			
1. Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho	83.33%	Wholesale of pharmaceuticals and medical devices, wholesale of medical machinery and equipment.
2. Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Cluster, Ba Che Commune, Quang Ninh Province	99.00%	Manufacture of pharmaceuticals, chemical drugs and medicinal materials . Manufacture of ovens, furnaces and kilns.
3. Golab Ung Bi Testing Center Joint Stock Company	Group 4, Zone 4, Bai Chay Ward, Quang Ninh Province	98.00%	General and specialized clinics
4. Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Park, Phase 1, Chau Thanh Commune, Can Tho City	98.00%	Manufacture of ovens, furnaces and kilns
5. Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1, Phuc Thinh, Cau Buou, Kien Hung Ward, Hanoi City	98.00%	General, specialist, and dental clinics
6. Hoa Binh Clinic Joint Stock Company	Ground floor, No. 83 Cu Chinh Lan Street, Group 13, Hoa Binh Ward, Phu Tho Province	98.00%	General, specialist, and dental clinics
7. Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho	98.00%	General, specialist, and dental clinics
8. Gia Lam High-Tech Clinic Joint Stock Company	18BT5, Phap Van-Tu Hiep Urban Area, Yen So Ward, Hanoi City	98.00%	General, specialist, and dental clinics


9. Medicare Clinic Can Tho Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Can Tho City	98.00%	General, specialist, and dental clinics
10. Medicare Hau Giang Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Zone 4, Vi Thanh Ward, Can Tho City	98.00%	General, specialist, and dental clinics
11. Medicare Clinic Joint Stock Company Soc Trang	1st floor, No. 438 Le Duan Street, Hamlet 4, Phu Loi Ward, Can Tho City	98.00%	General, specialist, and dental clinics
12. Golab Nga Bay Testing Center Joint Stock Company	No. 222, 30/4 Street, Zone 5, Nga Bay Ward, Can Tho City	98.00%	General, specialist, and dental clinics
13. Leopard Solution Joint Stock Company	No. 34, Street 79, Dinh Hamlet, Cu Chi Commune, Ho Chi Minh City	75.00%	Computer programming
Indirectly owned companies			
1. Famicare Thu Duc Joint Stock Company	28 Hien Vuong Street, Tang Nhon Phu Ward, Ho Chi Minh City	96.04%	General, specialist, and dental clinics
2. Medicare Friendship Clinic Joint Stock Company	No. 179 Giai Phong Street, Bach Mai Ward, Hanoi City	49%	General, specialist, and dental clinics
3. Golab Ninh Binh Testing Center Joint Stock Company	Ground floor, No. 140 Tue Tinh Street, Hoa Lu Ward, Ninh Binh Province	35%	General and specialized clinics
4. Golab Phap Van Testing Center Joint Stock Company	Ground floor, Lot BT 5, No. 18 Phap Van - Tu Hiep New Urban Area, Yen So Ward, Hanoi City	35%	General and specialized clinics
5. Phap Van Joint Stock Company	Ground floor, Lot BT 5, No. 17 Phap Van - Tu Hiep New Urban Area, Yen So Ward, Hanoi City	35%	General and specialized clinics
6. Go Vap Testing Center Joint Stock Company	1st Floor, No. 178 Nguyen Thai Son Street, Hanh Thong Ward, Ho Chi Minh City	35%	General and specialized clinics
7. Nghe An Clinic Joint Stock Company	Floor 1, No. 68 Ho Tong Thoc Street, Block 13, Vinh Phu Ward, Nghe An Province	35%	General and specialized clinics

8. Ba Dinh Clinic Joint Stock Company	No. 37A Doc Phu San, De La Thanh Street, Lang Ward, Hanoi City	35%	General and specialized clinics
9. Bac Lieu Testing Center Joint Stock Company	Ground floor, No. 210, Ba Trieu Street, Bac Lieu Ward, Ca Mau Province, Vietnam	35%	General and specialized clinics
10. Binh Duong Testing Center Joint Stock Company	634 Binh Duong Boulevard, Zone 5, Phu Loi Ward, Ho Chi Minh City, Vietnam	35%	General and specialized clinics
11. Tuyen Quang Joint Stock Company	2nd Floor, No. 23, Hoa Lu Street, Group 01, Minh Xuan Ward, Tuyen Quang Province, Vietnam	35%	General and specialized clinics
12. Golab Vung Tau Testing Center Joint Stock Company	745 Vo Van Kiet Street, Tam Long Ward, Ho Chi Minh City, Vietnam	49%	General and specialized clinics
13. Golab Ha Giang Testing Center Joint Stock Company	1st Floor, No. 75D Nguyen Thai Hoc Street, Group 16, Ha Giang 2 Ward, Tuyen Quang Province, Vietnam	49%	General and specialized clinics
14. Golab Tien Giang Testing Center Joint Stock Company	368A, Phuoc Hoa Hamlet, Trung An Ward, Dong Thap Province	35%	General and specialized clinics

2. INFORMATION ON THE GOVERNANCE MODEL, BUSINESS ORGANIZATION, AND MANAGEMENT STRUCTURE

Cơ cấu bộ máy quản lý

- a. AMV is organized and operates in accordance with the Enterprise Law. The Company's activities comply with the Enterprise Law, the Securities Law, and other relevant laws, as well as the Company Charter unanimously approved by the General Meeting of Shareholders. The Company's management structure is organized as follows:
- b. a. General Meeting of Shareholders: The General Meeting of Shareholders is the highest authority of the Company according to the Enterprise Law and the Company Charter. The General Meeting of Shareholders is responsible for discussing and approving medium- and long-term policies on the Company's development, deciding on capital structure, management structure, and the operation of the Company's activities.
- c. Board of Directors: The Board of Directors, elected by the General Meeting of Shareholders, is the governing body of the Company and has full authority to act on behalf of the Company to decide on all matters related to the Company's operations, except for those matters within the authority of the General Meeting of Shareholders. The Board of Directors is responsible for overseeing the Director and other management officers appointed by the Board, guiding existing and development policies to implement the decisions of the



c. Supervisory Board : The Supervisory Board is an agency directly under the General Meeting of Shareholders, elected by the General Meeting of Shareholders, and is responsible for assisting the General Meeting of Shareholders in supervising and evaluating the performance of the Board of Directors, the Director, and the Company's production and business activities objectively in order to ensure the interests of shareholders. Currently, the Company's Supervisory Board consists of three (03) members, each with a five (05) year term. The Supervisory Board operates independently of the Board of Directors and the Management Board. director.

d. Subcommittees of the Governing Council treatment :

- The Human Resources and Compensation Subcommittee is a body reporting directly to the Board of Directors, responsible to the Board of Directors and to the law for the exercise of its assigned rights and duties, specifically: advising and consulting the Board of Directors on the planning of human resource development strategies, senior management, labor management, and compensation and benefits within the company; and developing and implementing management policies related to the company's personnel organization . The functions and duties of the Human Resources and Compensation Subcommittee may be adjusted to suit changing circumstances. point

- The Development Policy Subcommittee is a body reporting directly to the Board of Directors, responsible to the Board of Directors and to the law for the exercise of its assigned rights and duties, specifically: determining development strategies, objectives, plans, and key performance indicators of the Company; identifying operational priorities; developing dividend policies; and evaluating the long-term effectiveness of the Company's operations . The functions and duties of the Development Policy Subcommittee may be adjusted as appropriate from time to time.

e. Director: The Director is appointed by the Board of Directors and is responsible for managing all production and business activities of the Company , implementing measures to achieve the Company's development goals , is subject to the supervision of the Board of Directors, and is accountable to the Board of Directors and to the law for the exercise of the rights and duties assigned to him/her. deliver.

f. Room sections ban:

- Sales Department: Manages the entire distribution channel and the nationwide network of general distributors, supporting distributors in marketing products and bidding for sales. product
- and long-term financial plans to ensure appropriate funding for production, business operations, and investment. private.
- Assisting the sales department in compiling sales and payment statistics. maths.
- Total fit information believe, fertilizer accumulation and establish newspaper urine plan maths give Board Supervisor
The director consults and makes decisions regarding business operations.
- Administrative and Human Resources Department: Advises and assists the Company's leadership in directing, managing, and overseeing administrative, managerial, legal, and document management tasks. storage.
- Develop strategies and control activities to ensure the company's facilities and working environment. ty.
- Planning and managing human resource activities in the company. ty,...
- Recruitment core pill new, send core pill Go dig create the lock learn; Nest function
Product presentation workshops.
- Technical Department: Research, develop plans and strategies for technological innovation and equipment upgrades to meet the company's production and business requirements. ty.
- Application use the advance set department learn skill technique, the bright ants, bright craft enter
production and business

3. DEVELOPMENT ORIENTATION DEPLOYMENT

3.1 Các mục tiêu chủ yếu

Quality – Efficiency – Reputation

- **Quality:** Includes product quality, service quality, and quality in relationships.
- **Efficiency:** Efficiency in product use, in production and business, in the work of each employee, in relationships with customers and partners, and in relationships between departments within the company.
- **Reputation:** Stabilizing and expanding the product market, striving to become the largest and most reputable manufacturer and distributor in the pharmaceutical and medical equipment sector nationwide.

3.2. Chiến lược phát triển trung và dài hạn

Striving to become a large and reputable distributor in the pharmaceutical and medical equipment sector nationwide:

- Regarding the market: Consolidating and developing the market, ensuring long-term and sustainable market exploitation.
- Regarding finance: Ensuring sufficient financial resources to serve AMV's objectives at each specific time.
- Regarding human resources: Enhancing the management capacity of the management team and

3.3. Sustainab le Developm ent Goals

As society develops, the issue of sustainable development receives increasing attention worldwide; sustainable development has inherent implications. jaw wide, outside terrible cell child People, commune festival then weak accuse lip school always Okay uncle important. Labour profession the more With development, the environment is threatened by pollution. In addition, overexploitation depletes resources, alters ecosystems, leading to droughts, natural disasters, and floods. overwhelm.

Recognizing the importance of sustainable development throughout its business operations, especially as AMV operates in the medical equipment industry with the goal of promoting human health, the company is very concerned about protecting a healthy living environment. This includes educating employees on maintaining workplace hygiene and participating in community environmental protection activities, specifically as follows:

- Using clean fuels to reduce waste contributes to environmental protection. school.
- Improve and enhance the living standards of employees and regularly implement social welfare programs in the local

4. RISK

4.1. Economic risk cell:

- **The global economy faces many risks.**

Against the backdrop of a still volatile global economy in 2025, key trends and events shaping the future are beginning to emerge. From uneven growth across regions and escalating geopolitical tensions to monetary policy adjustments and the rise of new industries, the 2025 global economic landscape reflects the complexity and multifaceted nature of a rapidly transforming global economy. According to the latest report from the Organization for Economic Cooperation and Development (OECD), global gross domestic product (GDP) growth is projected to reach approximately 3.2% in 2025.

The global economy continues to face major challenges from escalating geopolitical tensions.

The reversal in interest rate policies of many major economies signals a crucial adjustment period after a prolonged period of monetary tightening.

Amidst the unpredictable fluctuations of the global economy, Vietnam is also inevitably affected, facing issues such as growth and inflation control; manufacturing businesses lacking orders; businesses unable to access investment capital for production while capital costs continue to rise, etc.



✓ Current risks

- + Slow economic recovery, impacting market demand
- + Business disruptions (supply chain, imports)
- + Shortage of capital for production and business operations
- + Cash flow and liquidity risks
- + Slow innovation, failing to keep up with customer needs
- + Increased competition in the pharmaceutical and medical equipment industry
- + Cybersecurity risks, data breaches
- + Damage to corporate reputation and brand
- + Difficulty in attracting and retaining high-quality personnel
- + Risks of epidemics and health crises



✓ Future risks

- + Macroeconomic fluctuations, risk of growth slowdown
- + Exchange rate and interest rate fluctuations affecting financial costs
- + Risk of global supply chain disruptions
- + Increasing competitive pressure in the industry
- + Changes in legal policies and regulations in the healthcare and pharmaceutical sector
- + Risks related to technology, cybersecurity, and digital transformation; declining market demand or changes in customer behavior
- + Risk of capital shortages and difficulties in accessing credit
- + Pressure from input costs (raw material prices, logistics)
- + Difficulties in recruiting and retaining high-quality personnel
- + Risks to reputation and brand in the digital media environment
- + Risks from epidemics, health crises, or force majeure events

Deposit and lending interest rates in 2025 showed a gradual downward trend due to government policies and mechanisms facilitating businesses' access to capital for continued recovery of production and business activities. However, in reality, borrowing remains difficult for businesses due to banks' stringent appraisal requirements and concerns about the businesses' ability to recover. While 2025 recorded some positive macroeconomic indicators, the government continued to ease some policies in 2026, leading to a slight decrease in interest rates of 0.20 – 0.60 percentage points compared to the end of 2025; however, interest rates still remain high. In the process of production and business, most enterprises need to raise capital from banks. In particular, interest rates play a very important role in the development of the pharmaceutical industry. Fluctuations in interest rates will affect a company's ability to repay its debt, as well as the affordability of its products for investors and buyers.



Therefore, interest rate fluctuations directly affect financing costs, debt repayment capacity, and overall operational efficiency. Simultaneously, interest rates indirectly impact market purchasing power and customer investment decisions, particularly in the pharmaceutical and medical equipment sectors.

Overall, although interest rates are showing signs of cooling down, pressure on capital costs remains, requiring the Company to continue tight financial management and proactively balance its capital sources in the coming period.

Exchange Rate

AMV's main business activity is the trading of pharmaceuticals and medical equipment with relationships with foreign partners. In response to fluctuations in the foreign exchange market during the year, the Company proactively implemented exchange rate risk management measures, including closely monitoring exchange rate movements, forecasting input price trends, and developing appropriate import and inventory plans. As a result, the Company has mitigated the negative impacts of exchange rate fluctuations on cost of goods sold and business operations. Furthermore, in the context of the 2025 macroeconomic environment, the Vietnamese Government continues to manage a flexible monetary policy, contributing to the stability of the foreign exchange market, especially the USD/VND exchange rate. This has helped the company minimize exchange rate risks, creating more favorable conditions for the Company's import and business activities.

Overall, despite still being somewhat affected by exchange rate fluctuations, the Company has implemented appropriate solutions to control risks, contributing to the stability of its production and



5.1 Legal risks France

As a joint-stock company operating under a public company model and listed on the Hanoi Stock Exchange, AMV is subject to the regulations of the Enterprise Law, the Securities Law, and other related legal documents. Laws and subordinate regulations are still being finalized, and policy changes are always possible, potentially affecting the company's management and business operations to some extent.

To mitigate these legal risks, the company proactively and regularly updates its knowledge of legal regulations, researches changes in legislation, and promptly informs all its employees and shareholders

5.3 Rủi ro đặc thù

Specific risks are those risks commonly associated with the Company's business.

Due to its involvement in the healthcare sector, the Company also faces risks related to human health and life. Therefore, product quality is always a top priority for the Company, as all equipment supplied is from leading global manufacturers, meeting the stringent standards for medical equipment serving human needs in various countries.

Vietnam is in the process of integrating into the regional and global economy. Especially after Vietnam joined the WTO and the removal of tariff barriers, it will attract the participation of foreign pharmaceutical companies with strong financial resources and modern technology. Consequently, the business environment will become more fiercely competitive for domestic pharmaceutical manufacturers in terms of price, quality, and product range.

I. OPERATIONAL SITUATION YEAR

-
1. Production and business performance rack
 2. Organization and personnel the
 3. Love image head private, love image real presently the project
 4. Financial situation main
 5. Shareholder structure, changes in owner's investment capital. day
 6. Environmental impact report and society



1. PRODUCTION AND ECONOMIC ACTIVITIES SITUATION BUSINESS


Kết quả kinh doanh hợp nhất

Unit: VND

Target	2025	2024	Difference	Proportion
1. Revenue from sales and services	154,066,564,759	309,827,146,588	113,257,017,429	49.73%
2. Cost of goods sold	132,370,531,354	277,118,657,939	130,140,782,981	47.77%
3. Financial operating revenue	2,313,596,800	1,545,604,967	-2,410,554,850	149.69%
4. Total accounting profit before tax	-54,223,637,346	6,284,158,251	-8,284,672,718	-862.86%
5. Profit after corporate income tax	-54,503,718,617	3,334,576,695	-10,515,994,659	- 1634.50%

(Nguồn: Báo cáo tài chính hợp nhất quý 4 năm 2025 đã được công bố thông tin)

In 2025, both revenue and cost of goods sold decreased significantly compared to the previous year, while financial revenue increased slightly. However, the increase in provisions resulted in the Company recording negative pre-tax and after-tax profits, reflecting less than positive business performance during the year.




Kết quả kinh doanh công ty mẹ

Target	2025	2024	Difference	Proportion
1. Revenue from sales and services	25,762,745,204	169,327,403,953	-143,564,658,749	15.21%
2. Cost of goods sold	23,259,924,466	160,375,561,908	-137,115,637,442	14.50%
3. Financial operating revenue	17,010,120,993	10,000,513,202	7,009,607,791	170.09%
4. Total accounting profit before tax	-24,475,611,371	2,670,602,444	-27,146,213,815	-916.48%
5. Profit after corporate income tax	-24,475,611,371	1,885,741,329	-26,361,352,700	-1297.93%

(Nguồn: Báo cáo tài chính riêng quý 4 năm 2025 đã được công bố thông tin)

In 2025, the company's net revenue reached VND 25.762 billion, equivalent to a 15.21% increase compared to 2024. Net profit after tax was recorded as a negative VND 24.47 billion, compared to the previous year, mainly due to increased provisions for bad debts. This result shows that business operations in the year still face many




IMPLEMENTATION STATUS COMPARED TO THE PLAN

Financial indicators (Consolidated financial statements)	Plan 2025 (VND)	Performed 2025 (VND)	% Implement the plan
Total revenue	2 40,000,000,000	154,066,564,759	64.19 %
Net profit after tax	45,000,000,000	- 54.503.718.617	-121.12%

(Nguồn: Báo cáo tài chính hợp nhất quý 4 năm 2025 đã được công bố thông tin ; Kế hoạch kinh doanh năm 2025 đã được ĐHĐCĐ thường niên 2025 thông qua)

The company's business results for 2025 did not meet the set plan, with revenue reaching only 64.19% of the target. Net profit after tax was negative, equivalent to -121.12% of the target.

The main reasons stemmed from high cost of goods sold and the mandatory provision for bad debts, which affected business results during the year. These are also temporary factors, and the company expects to gradually improve its operational efficiency in the future.



2. ORGANIZATION AND PERSONNEL THE

HỘI ĐỒNG QUẢN TRỊ		BAN KIỂM SOÁT		BAN GIÁM ĐỐC	
NAKATANI YOSHITAKA	<ul style="list-style-type: none">- Chức vụ: Chủ tịch HĐQT- Năm sinh: 1964- Chuyên môn: Cử nhân- Số lượng CP sở hữu: 0- Tỷ lệ sở hữu: 0 %	LÊ THỊ HƯƠNG	<ul style="list-style-type: none">- Chức vụ: Trưởng BKS- Năm sinh: 1987- Chuyên môn: cử nhân- Số lượng CP sở hữu: 0- Tỷ lệ sở hữu: 0 %	ĐẶNG NHỊ NƯƠNG	<ul style="list-style-type: none">- Chức vụ: TV HĐQT kiêm Giám đốc- Năm sinh: 1956- Chuyên môn: cử nhân- Số lượng CP sở hữu: 0 cp- Tỷ lệ sở hữu: 0 %
ĐẶNG NHỊ NƯƠNG	<ul style="list-style-type: none">- Chức vụ: TV HĐQT kiêm Giám đốc- Năm sinh: 1956- Chuyên môn: cử nhân- Số lượng CP sở hữu: 0 cp- Tỷ lệ sở hữu: 0 %	LÊ HỮU TRÍ	<ul style="list-style-type: none">- Chức vụ: TV BKS- Năm sinh: 1989- Chuyên môn: cử nhân- Số lượng CP sở hữu: 0- Tỷ lệ sở hữu: 0 %	NGUYỄN THU HUYỀN	<ul style="list-style-type: none">- Chức vụ: Kế toán trưởng- Năm sinh: 1989- Chuyên môn: cử nhân- Số lượng CP sở hữu: 0- Tỷ lệ sở hữu: 0 %
LÊ KHÁNH NGUYỄN	<ul style="list-style-type: none">- Chức vụ: TV độc lập HĐQT- Năm sinh: 1956- Chuyên môn: Cử nhân- Số lượng CP sở hữu: 0- Tỷ lệ sở hữu: 0 %	NGUYỄN HƯƠNG GIANG	<ul style="list-style-type: none">- Chức vụ: TV BKS- Năm sinh: 1993- Chuyên môn: cử nhân- Số lượng CP sở hữu: 0- Tỷ lệ sở hữu: 0 %		

CHÍNH SÁCH NHÂN SỰ

+ Working Hours

The company operates on an 8-hour workday and 40-hour workweek.

+ Salary Policy

The average salary for the company in 2025 is VND 13,200,000 per month.

Employees work 5 days a week.

+ Reward Policy

The company's reward policy includes annual and extraordinary bonuses:

The company's annual bonus review and awarding are conducted at the end of the year, equivalent to the 13th month salary. The amount of the bonus depends on the company's business performance and the individual's successful completion of their work during the year.

Extraordinary bonuses and public recognition are promptly given to individuals with innovative technical improvements and increased labor productivity to motivate and encourage high-achieving employees.

+ Benefits Policy

All company employees are fully covered by insurance as per regulations, including social insurance, health insurance, and unemployment insurance.

+ Training Policy

In addition to salary and bonuses, employees at the company are also supported by the company with training and opportunities to attend courses to improve their professional skills.

Depending on the company's production and business needs, employees sent for training may receive their full salary and tuition fee support during their studies.

+ Leave, Holidays, and Tet (Lunar New Year)

+ Salary and Benefits Policy

All employees of the Company are employed under labor contracts, and the Company complies with legal regulations regarding social insurance and health insurance contributions.

The Company also has periodic and annual reward policies, as well as extraordinary bonuses for individuals and teams based on achievements in labor productivity, cost-saving practices, and innovative initiatives in technical and quality improvements.

Each year, the Company allocates a portion of its welfare fund to organize trips for outstanding employees.

In addition, the Company allocates a portion of its profits annually to assist employees facing difficult circumstances and provides preferential housing benefits for its employees.

+ Insurance and Benefits:

Employees with fixed-term contracts of 3 months or more are entitled to social insurance, health insurance, and unemployment insurance in accordance with regulations.

+ Employee Compliance with the Law:

All individuals in the Company strictly comply with labor laws, tax regulations, internal rules, regulations, and agreements, such as signing labor contracts and complying with all regulations regarding personal income tax, social insurance, health insurance, and unemployment insurance.

INVESTMENT SITUATION OF PROJECTS CASE

- + **Joint Investment Project for Wastewater Treatment System at the Obstetrics and Pediatrics Center - Phu Tho Provincial General Hospital: Implementing** Decision No. 1194/QD-SYT of the Director of the Phu Tho Provincial Department of Health dated October 18, 2018, approving the Joint Venture Project for Investment in a Wastewater Treatment System and Management and Operation of the Wastewater Treatment System at the Obstetrics and Pediatrics Center - Phu Tho Provincial General Hospital (now Phu Tho Provincial Obstetrics and Pediatrics Hospital). Joint Venture Agreement for the Construction, Management, and Operation of a Wastewater Treatment System No. 711/2018/BĐKTPT-VM dated October 26, 2018, between Phu Tho Provincial General Hospital and Viet My Hospital Investment Joint Stock Company and its Appendix Contract No. 01/PLHD/711-BVĐKPT-VM . The total estimated contract value is 17.49 billion VND, of which Phu Tho Provincial General Hospital contributes 5.63 billion VND in newly constructed infrastructure and Viet My Hospital Investment Joint Stock Company contributes 11.7 billion VND in the form of 100% new investment in machinery and equipment. The contract duration is 15 years. Phu Tho Provincial General Hospital has transferred the role of the main entity in the joint venture with Viet My Hospital Investment Joint Stock Company to Phu Tho Provincial Obstetrics and Pediatrics Hospital. The company has completed the handover to Phu Tho Provincial Obstetrics and Pediatrics Hospital. To date, the revenue generated from the project remains stable.
- + **Joint Venture Investment Project for the Reproductive Support Department at the Obstetrics and Pediatrics Center under Phu Tho Provincial General Hospital:** Implementing Decision No. 521/QD-SYT dated June 21, 2018, of the Phu Tho Provincial Department of Health approving the joint venture investment project for the Reproductive Support Department at the Obstetrics and Pediatrics Center (now the Obstetrics and Pediatrics Hospital) under Phu Tho Provincial General Hospital. Joint Venture Investment Contract No. 918/2018/BVĐKPT- VM dated June 29, 2018. The total estimated contract value is VND 99.1 billion. Phu Tho Provincial General Hospital contributes infrastructure with an estimated value of VND 37.1 billion. Viet My Hospital Investment Joint Stock Company contributes by investing in 100% new machinery and equipment with an estimated value of VND 62 billion. The contract is for a period of 10 years . The center has been operational since the end of 2019. The company has earned an estimated profit of approximately 3-8 billion VND per year.

❖ **Construction erect prize France complete intact about labour turmeric information believe, bag including part hard and software for hospitals, organizations, and management agencies to lease.**

With 20 years of experience in the healthcare sector in Vietnam, we have developed a comprehensive software solution:

- System system save storage and transmission image image PACS-VNA belong to practice group stand head position gender Mach7 - USA (FDA certified);
 - HIS Hospital Management Software (LeoHospital);
 - Laboratory management software LIS;
 - Electronic signature software on the platform Blockchain;
 - Camera-based facial recognition softwareWHO;
 - Electronic medical records EMR;
 - Cashless payment software face;
 - Centralized data management software HDMS;
 - The hardware infrastructure is officially supplied by the following vendors: DELL/HP/INTEL/MICROSOLF/CI
- PACS (Picture Archiving and Communication System) in many major provinces and cities such as Phu Tho, Nghe An, Quang Ninh, Vung Tau, An Giang, Can Tho, Hanoi, etc., with some projects already approved by the Ministry of Health, recognized as electronic medical records, and agreed to be covered by insurance companies. In the near future, the company will... There are plans to widely implement this model in other areas across the country.country.



SUBSIDIARY AND AFFILIATED COMPANIES

Company	Place of establishment and operation	Benefit rate	Main business activities
Companies that directly own			
1. Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Viet Tri City, Phu Tho Province	83.33%	Wholesale of pharmaceuticals and medical devices, wholesale of medical machinery and equipment.
2. Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Cluster, Nam Son Commune, Ba Che District, Quang Ninh Province	99.00%	Manufacture of pharmaceuticals, chemical drugs and medicinal materials . Manufacture of furnaces and kilns.
3. Kyoto Bai Chay Clinic Joint Stock Company	Group 4, Zone 4, Bai Chay Town, Ha Long City, Quang Ninh Province	98.00%	General and specialized clinics
4. Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Park – Phase 1, Dong Phu Commune, Chau Thanh District, Hau Giang Province	98.00%	Manufacture of ovens, furnaces and kilns
5. Ha Dong Clinic Joint Stock Company	3rd floor No. 1 Phuc Thinh Street, Kien Hung Ward, Ha Dong District, Hanoi City	98.00%	General, specialist, and dental clinics
6. Hoa Binh Clinic Joint Stock Company	No. 83 Cu Chinh Lan Street, Dong Tien Ward, Hoa Binh City, Hoa Binh Province	98.00%	General, specialist, and dental clinics
7. Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Viet Tri City, Phu Tho Province	98.00%	General, specialist, and dental clinics
8. Gia Lam High-Tech Clinic Joint Stock Company	18 BT5 Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City	98.00%	General, specialist, and dental clinics
9. Medicare Clinic Can Tho Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Ninh Kieu District, Can Tho City	98.00%	General, specialist, and dental clinics
10. Hau Giang Medicare Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Area 4, Ward III, Vi Thanh City, Hau Giang Province	98.00%	General, specialist, and dental clinics

11. Medicare Clinic Soc Trang Joint Stock Company	1st floor, No. 438 Le Duan Street, Hamlet 4, Ward 4, Soc Trang City, Soc Trang Province	98.00%	General, specialist, and dental clinics
12. Golab Nga Bay Testing Center Joint Stock Company	No. 222, 30/4 Street, Zone 5, Lai Hieu Ward, Nga Bay City, Hau Giang Province	98.00%	General, specialist, and dental clinics
13. Leopard Solution Joint Stock Company	No. 34, Street 79, Dinh Hamlet, Tan Phu Trung Commune, Cu Chi District, Ho Chi Minh City	75.00%	Computer programming
Indirectly owned companies			
1. Famicare Thu Duc Joint Stock Company	28 Hien Vuong Street, Tang Nhon Phu Ward, Ho Chi Minh City, Vietnam	96.04%	General, specialist, and dental clinics

SUBSIDIARY COMPANIES

(Summary of the operations and financial situation of the subsidiaries as of December 31, 2025)

Công ty CP nghiên cứu áp dụng Công nghệ mới Sông Hậu			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	166.127.212.404	164.213.183.538	101,17%
Tổng nguồn vốn	166.127.212.404	164.213.183.538	101,17%
Doanh thu thuần	12.740.000.000	4.310.000.000	295,59%
Lợi nhuận trước thuế	-6.701.449.985	583.169.558	-1149,14%

(Source: Newspaper urine talent main belong to labour ty CPNCAD CNM River (Hau))

Công ty CTCP phòng khám medicare Cần thơ			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	78.547.970.970	83.632.074.718	93,92%
Tổng nguồn vốn	78.547.970.970	83.632.074.718	93,92%
Doanh thu thuần	603.580.000	4.927.773.700	12,25%
Lợi nhuận trước thuế	-3.164.342.094	2.325.172.779	-136,09%

(Source: Newspaper urine talent main belong to Joint Stock Company PK Medicare Needed Verse)

Công ty CTCP phòng khám medicare Sóc Trăng			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	81.798.996.248	80.763.054.334	101,28%
Tổng nguồn vốn	81.798.996.248	80.763.054.334	101,28%
Doanh thu thuần	2.928.179.948	7.700.600.000	38,03%
Lợi nhuận trước thuế	-578.630.005	2.012.806.333	-28,75%

Công ty CTCP phòng khám medicare Hậu Giang			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	82.794.390.020	82.794.390.020	100,00%
Tổng nguồn vốn	82.794.390.020	82.794.390.020	100,00%
Doanh thu thuần	4.107.448.200	7.700.600.000	53,34%
Lợi nhuận trước thuế	-3.764.710.773	1.967.496.454	-191,35%

(Source: Newspaper urine talent main belong to Joint Stock
Company PK Medicare Soc Moon

(Source: Financial report of PK Joint Stock Company) MD Hau Giang)

SUBSIDIARY COMPANIES

(Summary of the operations and financial performance of the subsidiaries as of December 31, 2023)

Công ty CP phòng khám medicare Ngã Bảy			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	82.110.742.543	82.319.530.352	99,75%
Tổng nguồn vốn	82.110.742.543	82.319.530.352	99,75%
Doanh thu thuần	456.133.867	14.624.968.994	3,12%
Lợi nhuận trước thuế	-460.668.445	2.330.393.994	-19,77%

(Source: Newspaper urine talent main belong to Joint Stock Company PK Medicare Fall Seven)

Công ty CP phòng khám Hà Đông			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	76.330.428.551	83.892.811.805	90,99%
Tổng nguồn vốn	76.330.428.551	83.892.811.805	90,99%
Doanh thu thuần	317.427.000	5.138.726.080	6,18%
Lợi nhuận trước thuế	-5.008.709.670	2.789.782.599	-179,54%

(Source: Newspaper urine talent main belong to Ha Phu Joint Stock Company Winter)

Công ty CP phòng khám Hòa Bình			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	133.502.195.068	141.110.512.542	94,61%
Tổng nguồn vốn	133.502.195.068	141.110.512.542	94,61%
Doanh thu thuần	19.553.446.000	4.373.834.000	447,06%
Lợi nhuận trước thuế	9.035.887.208	-9.048.031.155	-99,87%

(Source: Newspaper urine talent main belong to PK Hoa Joint Stock Company Jar)

Công ty CP phòng khám bãi cháy kyoto			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	45.885.922.210	50.771.075.388	90,38%
Tổng nguồn vốn	45.885.922.210	50.771.075.388	90,38%
Doanh thu thuần	0	5.600.600.000	
Lợi nhuận trước thuế	-5.363.882.330	1.705.360.656	-314,53%

(Source: Newspaper urine talent main belong to Bai Chay Parking Joint Stock Company Kyoto)

SUBSIDIARY COMPANIES				(Summary of the operations and financial performance of the subsidiaries as of December 31,			
2024)							
Gia Lam High-Tech Clinic Joint Stock Company				Công ty CP phát triển công nghệ Hạ Long kyoto			
Target	2024	2023	proportion	Chỉ tiêu	2025	2024	tỷ trọng
Total assets	87,823,256,590	78,255,841,016	112.23%	Tổng tài sản	104.160.277.168	101.623.798.998	102,50%
Total capital	87,823,256,590	78,255,841,016	112.23%	Tổng nguồn vốn	104.160.277.168	101.623.798.998	102,50%
Net revenue	7,700,600,000	0		Doanh thu thuần	3.220.000.000		
Profit before tax	1,626,451,285	-355,401,553	-457.64%	Lợi nhuận trước thuế	2.120.350.863	-8.761.440.737	-24,20%
(Source: Newspaper urine talent main belong tolabour ty CP PK KTC Gia Lam				(Source: Financial report of the Joint Stock Company for			
Viet Tri Clinic Joint Stock Company				Industrial Development)			
Target	2025	2024	proportion	Ha Long art (Yoto)			
Total assets	110,247,026,120	118,551,121,172	93.00%				
Total capital	110,247,026,120	118,551,121,172	93.00%				
Net revenue	4,103,000	7,700,600,000	0.05%				
Profit before tax	-18,823,619,777	2,029,008,893	-927.72%				
(Source: Newspaper urine talent main belong toJoint Stock Company VxTri Clinic							

SUBSIDIARY COMPANIES

(Summary of the operations and financial situation of the subsidiaries as of December 31, 2024)

Công ty CP Leopard solutions			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	17.215.940.580	9.890.420.695	174,07%
Tổng nguồn vốn	17.215.940.580	9.890.420.695	174,07%
Doanh thu thuần	14.767.413.452	7.352.322.476	200,85%
Lợi nhuận trước thuế	3.532.210.959	-96.240.925	-3670,18%

(Source: Newspaper urine talent main belong to labour ty Joint Stock Company Leopard solutions)

Công ty CP đầu tư BV Việt Mỹ			
Chỉ tiêu	2025	2024	tỷ trọng
Tổng tài sản	413.737.339.754	428.658.602.606	96,52%
Tổng nguồn vốn	413.737.339.754	428.658.602.606	96,52%
Doanh thu thuần	74.453.888.756	46.125.022.238	161,42%
Lợi nhuận trước thuế	-8.801.045.530	-11.579.965.641	76,00%

(Source: Financial report of Investment Joint Stock Company) Viet My Hospital

Công ty Famicare Thủ Đức			
Chỉ tiêu	2025	2024	Tỷ trọng
Tổng tài sản	8.744.780.805	9.310.455.414	93,92%
Tổng Nguồn vốn	8.744.780.805	9.310.455.414	93,92%
Doanh thu thuần		0	
Lợi nhuận trước thuế	-530.452.385	-276.978.255	191,51%

(Nguồn: Báo cáo tài chính Công ty Famicare Thủ Đức)

- **FINANCIAL SITUATION MAIN**

a) Financial situation in the consolidated report for 2025 - Based on the unaudited Q4/2025 financial report.

No.	Target	2025 (VND)	2024 (VND)	2025/2024
1	Total asset value	1,905,760,203,871	1,955,640,634,757	97.45%
2	Equity	1,619,380,790,087	1,672,709,810,324	96.81%
3	Net revenue	154,066,564,759	309,827,146,588	49.73%
4	Net profit from business operations	-49,997,085,679	-6,636,221,641	753.4%
5	Other profits	-4,226,551,667	12,920,379,892	-32.71%
6	Profit before tax	-54,223,637,346	6,284,158,251	-862.86%
7	Net profit after tax	-54,503,718,617	3,334,576,695	-1634.5%

(Source: Consolidated financial report for Q4 2025, information disclosed in 2025)

In 2025, revenue decreased sharply to 49.73% compared to 2024, while all profit indicators turned negative. Total assets and equity decreased slightly, reflecting business operations not achieving the expected results.

b) Basic indicators

Indicators	Unit	2024	2025
<i>1. Solvency ratio</i>			
+ Current ratio: Short-term assets/Short-term liabilities	time	6.1	4.19
+ Quick Ratio <u>TSNH - Inventory</u> Short-term debt	time	5.78	3.86
<i>2. Capital structure indicators</i>	time		
+ Debt/Total Assets Ratio	time	0.14	0.1 5
+ Debt/Equity Ratio	time	0.17	0.1 8
<i>3. Performance indicators</i>	time		
+ Inventory turnover Cost of goods sold/Average inventory	time	6.14	4.57
+ Net revenue/Total assets	time	0.1 6	0.08
<i>4. Profitability Indicators</i>	time		
+ Net profit margin/Net revenue ratio	time	0.01	
+ Net profit margin/Equity ratio	time	0.02	
+ Net profit after tax/Total assets ratio	time	0, 017	
+ Profit margin from business operations/Net revenue	time		

(Nguồn theo báo cáo tài chính hợp nhất quý 4 năm 2025 đã được công bố thông tin)

NECK STRUCTURE WINTER

- Stock ticker: AMV
- Listing exchange: HNX
- First trading day: December 30, 2009
- Total number of shares: 131,105,650 shares.
- Type of shares: Common shares.
- Number of shares outstanding : 131,105,650 shares
- Treasury stock volume: 0 shares
- Source: Shareholder list as of May 30, 2025

No.	Criteria	Number of shareholders (people)	Number of shares	Ownership percentage
I	Domestic shareholders	10,010	130,731,257	99.71%
1	State shareholders	0		
2	Institutional shareholders	4	202,260	0.15%
3	Individual shareholders	10,006	130,528,997	99.56%
II	Foreign shareholders	46	374,393	0.29%
1	Institutional shareholders	11	193,603	0.15%

Report on stock dividend payments in Q1/2021

- Record date for dividend payment: November 6, 2020
- Last registration date: November 6, 2020
- Purpose: To pay the 2019 dividend in shares.
- Execution ratio: 40%/share (for every 100 shares held, 40 new shares will be awarded)
- Number of shares distributed: 15,184,771 shares
- Number of shareholders to whom dividends are distributed: 4,708 shareholders
- Method for handling fractional shares: The number of shares each shareholder receives when dividend shares are issued will be rounded down to the nearest whole number. Any fractional shares (the decimal portion) will be canceled and not issued.
- Date of registration for additional shares issued to pay dividends at the Vietnam Securities Depository Center: February 9, 2021
- The official trading date for shares issued as dividends for 2019 on the HNX is March 24, 2021.

2	Individual shareholders	35	180,790	0.14%
III	Treasury stock			
	Total	10,056	131,105,650	100%

Report on cash dividend payments

- Record date for dividend payment: Date November 6, 2020
- Last registration date: Date November 6, 2020
- Purpose: To pay the 2019 dividend in shares. ticket
- Execution rate: 20%/share (each share receives 2,000). copper)
- Installment payment 1:
- ✓ 10% per share ticket
- ✓ Payment date: January 28, 2026
 - Installment payment 2:
- ✓ 10% per share ticket
- ✓ Payment date: 28/07/2026

Report on the results of the private placement of shares to existing shareholders.

- Date of completion of the offering: June 7, 2022
- Total number of shares distributed: 39,996,789 shares, representing 99.992 % of the total shares offered. (Including 28,512,044 unsold shares that were redistributed and subject to a 1-year transfer restriction: until June 8, 2023)
- Issue price: 10,000 VND/share
- Total proceeds from the offering: VND 399,967,890,000
- Transfer restrictions: Privately issued shares are subject to a one-year transfer restriction from the date of completion of the offering (from June 7, 2022 to June 8, 2023).
- Purpose of the offering: The total amount raised from the private placement is VND 399,967,890,000. The entire amount will be used by the company for the following purposes: Investing in subsidiaries; Supplementing working capital to support production and business operations.

Report on the results of the private placement of shares to strategic shareholders.

- Date of completion of the offering: March 1, 2021
- Total number of shares distributed: 37,962,045 shares, representing 100% of the total shares offered.
- Issue price: 10,000 VND/share
- Total proceeds from the offering: VND 379,620,450,000
- Transfer restrictions: Privately issued shares are subject to a one-year transfer restriction from the date of completion of the offering (from March 1, 2021 to March 1, 2022).
- Purpose of the offering: The total amount raised from the private placement is VND 379,620,450,000. The company will use this entire amount for the following purposes: Joint investment in a project to build a Japanese-technology negative pressure waste incineration system at the Viet Hung Waste Treatment Plant, Dong Anh, Hanoi; and supplementing working capital for production and business operations.



- **REPORT ON ENVIRONMENTAL AND SOCIAL IMPACT FESTIVAL**

Quản lý nguồn nguyên vật liệu:



- Tổng lượng nguyên vật liệu được sử dụng để sản xuất và đóng gói các sản phẩm và dịch vụ chính của tổ chức trong năm: không
- Báo cáo tỉ lệ phần trăm nguyên vật liệu được tái chế sử dụng để sản xuất sản phẩm và dịch vụ chính của tổ chức: không



Tiêu thụ năng lượng

- Năng lượng tiêu thụ trực tiếp và gián tiếp: không
- Năng lượng tiết kiệm được thông qua các sáng kiến sử dụng năng lượng hiệu quả: không
- Các báo cáo sáng kiến tiết kiệm năng lượng: không



Tuân thủ pháp luật về bảo vệ môi trường

- Số lần bị xử phạt vi phạm do không tuân thủ luật pháp và các quy định về môi trường: Không có
- Tổng số tiền do bị xử phạt vi phạm do không tuân thủ luật pháp và các quy định về môi trường: Không có

Policies related to workers:

- Number of workers, average wage for workers. movement
- Number of employees at the parent company as of December 31, 2025: **28 People**
- Average salary for workers: 13,000,000 VND/person/month
- Training policy create
- Recognizing that training to improve the professional skills and conduct of employees plays a crucial role in business management and operations, business.

b) Main book tuberculosis movement aiming guarantee tell strength Strong, ten of workers

- With the principle of placing employees as the foundation and driving force for the company's development , AMV always focuses on recruitment, ensuring that the recruiters have sufficient skills and qualifications to serve the company's development direction . Given the industry's demand for highly skilled labor, the company aims to offer competitive salaries to attract high-quality, experienced, and senior employees. Building a team of experienced and highly effective managers is crucial. job.
- Investing in and developing human resources is one of the core elements of the Company in order to meet the ever-evolving needs of society. The company regularly organizes professional development courses with practical content to ensure effective application in the workplace. In addition, the company offers advanced training courses both domestically and internationally to help employees continue to develop their professional skills and expertise. power.

- Hoạt động đào tạo người lao động
- Thực hiện tốt công tác nhân sự và tuyển dụng lao động, xây dựng kế hoạch đào tạo và phát triển nguồn nhân lực dài hạn và đáp ứng được sự phát triển của công ty.
- Công ty xây dựng và thực hiện các kế hoạch đào tạo phát triển nguồn nhân lực, hỗ trợ tốt nhất cho người lao động trong công việc phát triển sự nghiệp.




- Người lao động trong công ty tùy theo tính chất công việc được trang bị đầy đủ các thiết bị, vật dụng cần thiết để phục vụ cho công việc. Cán bộ công tác tại các bệnh viện đều được trang bị bảo hộ lao động đầy đủ, đúng chủng loại theo quy định

2. REPORT AND EVALUATION BY THE BOARD OF DIRECTORS DIRECTOR

1. Review of business performance for the year 2025

2. Financial situation main

3. Improvements to the company's structure,
management policies, and
development plan for 2026.



EVALUATION OF BUSINESS PERFORMANCE FOR THE YEAR 2025

- **An overall analysis of the company's performance compared to the plan and the results. previous business operations This:**

In 2025, the global situation continues to be complex and unpredictable, with many risks and uncertainties. Military conflicts continue to escalate, strategic competition between major powers intensifies, many countries strengthen protectionist trade policies, public debt and budget deficits increase, some major economies decline, and global supply chains experience localized disruptions, all impacting world peace, stability, and economic growth. Furthermore, natural disasters and extreme weather events severely affect the lives of people and socio-economic development in many countries.

In this context, the Company is also inevitably affected by these negative impacts.

Recognizing the aforementioned difficulties, in addition to ensuring the health and safety of its staff, the Board of Directors proactively developed operational plans, held monthly meetings to evaluate business results, and intensified efforts to reduce unnecessary expenses in order to make timely adjustments. As a result, the company gained new customers and expanded its business areas, contributing to the achievement of its set targets.

Financial management, capital preservation, and development were carried out in accordance with the State's regulations and policies on financial management. The company's revenue and expenditure were well managed, and all tax and budget obligations to the State were fulfilled.

Marketing and market expansion were given special attention by the Board of Directors, who directly implemented the company's main business areas. The company continued to grow steadily in scale, and business efficiency improved significantly. Employees were guaranteed employment and stable income.



Marketing and market expansion are given special attention by the company's Board of Directors and are directly implemented in the company's main business areas. The company continues to grow steadily in scale, and business efficiency has improved significantly. Employees are guaranteed employment and stable income.


- **The progress the company has made**

Against the backdrop of significant instability in the global and domestic political and economic situation, resulting in sluggish growth, rising costs, and numerous indirect external challenges, the current business results reflect the efforts of all employees and the Board of Directors, along with the close and effective guidance of the Board of Trustees. Following the growth in 2025, the Board of Directors is confident that the company will achieve many more successes and high economic efficiency in 2026.

• FINANCIAL SITUATION


Tình hình tài sản

No.	Item	Year-end amount (VND)	Beginning of year amount (VND)	Percentage (%)
1	Current assets	657,929,057,604	951,892,884,765	69.12%
2	Long-term assets	1,247,831,146,267	1,003,747,749,992	124.32%
	Total assets	1,905,760,203,871	1,955,640,634,757	97.45%



Tình hình nợ

No.	Item	Year-end amount (VND)	Beginning of year amount (VND)	Percentage (%)
1	Short-term debt	156,906,855,040	156,093,026,150	100.05%
2	Long-term debt	129,472,558,744	126,837,798,283	98.95%
	Total liabilities	286,379,413,784	282,930,824,433	99.55%



(Nguồn: Báo cáo tài chính hợp nhất quý 4 năm 2025 đã được công bố)

Improvements in organizational structure, policies, and management .

- Departmental restructuring: From 2025 onwards, the company has restructured its departments to be more streamlined, in line with the current business situation and future business direction. next.
- Management is addressed in the following stages: Establishing the company's goals, development strategies, long-term, medium-term, and short-term plans; Developing regulations, rules, and documents concerning the functions of each department in accordance with current legal regulations; Organizing and handling tasks within the department's responsibilities and authority; Analyzing, synthesizing, updating information, and evaluating the company's performance periodically and/or as requested by management. ty.
- Enhance the sense of responsibility and professionalism of all staff and employees in the workplace. ty.
- Application use labour turmeric in chest reason, thing onion and supply grant pandemic the case guest row.

3. IMPROVE ORGANIZATIONAL STRUCTURE , POLICIES, MANAGEMENT AND ANNUAL OPERATIONAL PLAN 2025



AMVI BIOTECH, INC – A PIONEER AND LEADER

Future development plan:

- Closely monitor the market to develop business strategies aimed at maximizing profits, actively prepare for and seek potential customers, and ensure the smooth operation of the company's business activities. company;
- Expanding the company's operations across all three regions of Vietnam: North, Central, and South. Male;
- Continue investing, expanding business areas, accelerating the completion of ongoing projects, and investing in new projects that are about to be launched. declare;
- Improving the quality and professionalism of human resources within the company , training human resources with a long-term vision, and sending technical staff to participate in training courses abroad. outside;
- Continuously improving service quality. service;
- Effective cost management, thorough cost saving, and guaranteed

business efficiency.

- Ensuring jobs and income for workers. movement.

3. BOARD OF DIRECTORS EVALUATION TREATMENT

a. Board of Directors' assessment of the Company's performance. ty

In 2025, despite the volatile and challenging global and domestic economic context, the Company strived to fulfill its assigned tasks and targets. The Board of Directors complied with legal regulations and the Company's Charter to implement, inspect, and supervise; and supported the Company's Executive Board in the process of carrying out production and business activities. Based on the 2025 production and business plan approved by the General Meeting of Shareholders, the Board of Directors issued Resolutions/Decisions directing the Executive Board to implement tasks promptly and effectively. 2025 remains a challenging year for the world in general and Vietnam in particular: high inflation, tight fiscal policies by the government, rising interest rates on capital mobilization, and increasing commodity costs, all of which have made it difficult for the company to maintain its supply chain speed amidst disruptions to foreign trade, difficulties with customer contract cancellations, and financial challenges. Despite this difficult year, the company still has a strategy to optimize profits and ensure the interests of shareholders and investors.

In terms of corporate governance, the Board of Directors and the Management Board have finalized the system of regulations.

Internal regulations, organizational structure and personnel review.

Financial management and supervision are carried out strictly in accordance with current regulations, the Company's financial situation is healthy, and all financial indicators for 2025 reflect the Company's financial strength and sustainability.

In addition, the company consistently maintains a relatively proactive and responsible approach to occupational safety management, product quality, and environmental protection.

b. Board of Directors' assessment of the company's management team's performance.

The Board of Directors is responsible for directing and supervising the activities of the Company's Management Board in business operations to align with the objectives and plans approved by the General Meeting of Shareholders. The Board of Directors highly appreciates the efforts and endeavors of the Management Board in managing the Company's operations to best fulfill the assigned production and business plan for 2025.

To achieve success in production and business, the Board of Directors promptly implemented the resolutions of the Board of Trustees, operating within its functions and duties, in accordance with regulations, the Enterprise Law, and the Company's Charter. The Board of Directors maintained weekly and monthly briefing meetings to resolve and address difficulties and obstacles in business operations. The Board of Directors and the Board of Trustees have fully and correctly performed their functions, duties, and powers as stipulated. In its leadership and management, the Board of Directors and the Management Board have shown high levels of consensus, proposing appropriate solutions and decisions in each case. The Management Board is dynamic, creative, and proactive, leading the work decisively and correctly, contributing to the achievement of business targets in the past year. The Board of Directors highly appreciates and values the efforts of the Management Board in directing business operations to achieve the planned targets amidst the volatile economic situation in 2025.

4. PUBLIC ADMINISTRATION Y

1. BOARD OF DIRECTORS TREATMENT

2. INSPECTION COMMITTEE REVIEW

3. TRANSACTIONS , REMUNERATION , AND BENEFITS
OF THE BOARD OF DIRECTORS AND
MANAGEMENT COMMITTEE
CONTROL



1. BOARD OF DIRECTORS TREATMENT

Board of Directors personnel:

At the 2025 Annual General Meeting, the following Independent Members of the Board of Directors/Members of the Board of Directors were elected for the 2025-2030 term:

Board Meetings 2025:

STT	Thành viên HĐQT	Chức vụ	Ngày bắt đầu/không còn là TV HĐQT/TV độc lập HĐQT	
			Ngày bổ nhiệm	Ngày miễn nhiệm
01	Nakatani Yoshitaka	Chủ tịch HĐQT	29/07/2025	
02	Đặng Nhị Nương	TV HĐQT	29/07/2025	
03	Lê Khánh Nguyên	TV độc lập HĐQT	29/07/2025	

STT	Thành viên HĐQT	Số buổi họp HĐQT tham dự	Tỷ lệ tham dự họp
1	Nakatani Yoshitaka	14/14	100%
2	Đặng Nhị Nương	14/14	100%
3	Lê Khánh Nguyên	14/14	100%



Board of Directors' activities in 2025 :

No.	Resolution number	Day	Content
1	0601/2025/NQ-HĐQT	January 6, 2025	Regarding the transfer of capital contributions in Phu Tho Provincial Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company.
2	0701/2025/NQ-HĐQT	January 7, 2025	Regarding the termination of operations of the Representative Office
3	Resolution 1701/2025/NQ-HĐQT	January 17, 2025	Regarding the second transfer of capital contribution in Phu Tho Provincial Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company.
4	2502/2025/NQ-HĐQT	February 25, 2025	Regarding the change in the payment schedule for cash dividends in 2019.
5	2502.01/2025/NQ-HĐQT	February 25, 2025	Regarding the divestment of investment in Vietnam National Software Production Joint Stock Company.
6	2403/2025/NQ-HĐQT	March 24, 2025	Regarding the extension of the time for holding the 2025 Annual General Meeting of Shareholders.
7	1604/2025/NQ-HĐQT	April 16, 2025	Regarding the early withdrawal of capital contributions at Phu Tho Provincial Obstetrics and Pediatrics Hospital.
8	2904/2025/NQ-HĐQT	April 29, 2025	Regarding the change of the auditing firm for the Company's 2024 financial statements.
9	1106/2025/NQ-HĐQT	June 11, 2025	Regarding the change of the company's chief accountant.
10	0307/2025/NQ-HĐQT	03/07/2025	Subject: Approval of the plan to organize the second Annual General Meeting of Shareholders in 2025

11	3007/2025/NQ-HĐQT	July 30, 2025	Subject: Approval of the Board of Directors' personnel structure for the 2025-2030 term and Change of branch address
12	3007.01/2025/NQ-HĐQT	July 30, 2025	Subject: Signing of the contract for auditing the Company's financial statements for 2025
13	1710/2025/NQ-HĐQT	October 17, 2025	Subject: Change of company chief accountant
14	2612/2025/NQ-HĐQT	December 26, 2025	Subject: Approval of a loan at Capella Group Joint Stock Company

2. INSPECTION COMMITTEE REVIEW

Supervisory Board personnel:

At the 2025 Annual General Meeting, the Supervisory Board for the 2025-2030 term was elected as follows:

STT	Thành viên HĐQT	Chức vụ	Ngày bắt đầu/không còn là TV Ban kiểm soát	
			Ngày bổ nhiệm	Ngày miễn nhiệm
01	Lê Thị Hương	Trưởng ban kiểm soát	29/07/2025	
02	Vũ Thu Thủy	TV BKS	29/07/2025	
03	Lê Hữu Trí	TV BKS	29/07/2025	
04	Nguyễn Hương Giang	TV BKS		29/07/2025

Supervisory Board Meetings in 2025:

STT	Thành viên HĐQT	Số buổi họp HĐQT tham dự	Tỷ lệ tham dự họp	Lý do không tham dự họp
01	Lê Thị Hương	08/08	100%	
02	Lê Hữu Trí	02/02	25%	Được bổ nhiệm ngày 29/7/2025
03	Nguyễn Hương Giang	08/08	100%	
04	Vũ Thu Thủy	06/06	75%	Miễn nhiệm ngày 29/7/2025

- **Supervisory activities of the Supervisory Board over the Board of Directors, the Executive Management Board, and shareholders:**
- The Supervisory Board supervises the Board of Directors and the Management Board in the management and operation of the company; and is accountable to the General Meeting of Shareholders for the performance of its assigned duties.
 - Inspect and monitor the company's operations and financial situation, and provide appropriate recommendations.
 - Monitoring compliance with General Meeting resolutions and laws in the management and operation of the company's business by the Board of Directors and the Management Board. Reviewing the appropriateness of decisions made by the Board of Directors and the Management Board in management work.
 - The Supervisory Board supervised the counting of the written shareholder opinions.
 - The supervisory board examines the reasonableness, legality, honesty, and degree of prudence in the management and operation of business activities, as well as in accounting and statistical work.
 - Financial reporting oversight aims to assess the accuracy and integrity of financial data, ensuring compliance with Vietnamese accounting standards.
 - We are always ready to receive feedback from shareholders/groups of shareholders and to conduct inspections and evaluations as requested by shareholders/groups

of shareholders.

- For shareholders: In 2025 , the Company's Supervisory Board received feedback from shareholders Nguyen Thi Kim Lien and Nguyen Ngoc Vinh. The Company has sent written responses to these shareholders.

- Coordination of activities between the Supervisory Board and the Board of Directors, the Executive Management Board, and other management personnel:

- The Supervisory Board has proactively coordinated closely with the Board of Directors and the Company's Management Board in performing its assigned functions and duties, and conducting inspection and supervision activities as prescribed.
- The Supervisory Board is always kept updated on the Company's operations by the Board of Directors and the Management Board, and is provided with complete information and documents to support its inspection and supervision work.
- The Supervisory Board regularly coordinates with the Board of Directors in directing and supervising departments and subordinate units to ensure the implementation of the Company's resolutions and development plans in each specific period.
- The Supervisory Board is invited to attend all meetings of the Board of Directors and provide input on matters related to the management, operation, and business of the Company to ensure that the Company's activities are appropriate and meet the interests of shareholders.

3. REMUNERATION FOR THE BOARD OF DIRECTORS, SUPERVISORY BOARD, AND MANAGEMENT BOARD DIRECTOR

3.1 Remuneration, bonuses, and benefits other:

The Board of Directors, Supervisory Board, and Management Board are entitled to remuneration in accordance with the resolutions of the General Meeting of Shareholders and the operating regulations of the Board of Directors and Supervisory Board.

3.2 Stock transactions by domestic shareholders set: none Have

3.3 Insider trading contracts: none Have

3.4 Major transaction contracts with subsidiaries: none Have

3.5. Implementing corporate governance regulations

The company's management and governance structure is established and complies with the provisions of the Enterprise Law, the Securities Law, and other relevant specialized legal regulations.

In addition to fulfilling all disclosure obligations in the securities sector, the Company's governance system is tightly controlled, and the management and operational activities of the Board of Directors and the Management Board are always transparent and carefully monitored. Furthermore, with many years of experience in the medical equipment, pharmaceutical, and biochemical industries, the Company's management team always strives to minimize risks related to people's health and lives. People.

Board members, Supervisory Board members, the Board of Directors, the person in charge of corporate governance, and other officers fully participated in training courses and seminars on corporate governance, information disclosure, and financial reporting to ensure compliance with the new securities laws. In addition, the company's leadership also directed the organization of internal training courses to disseminate knowledge on corporate governance and update regulations on information disclosure in the securities market, thereby improving the professional skills of the company's staff.



4. FINANCIAL REPORT MAIN

REPORT PREPARED BY THE UNIT

1. BALANCE SHEET MATHS
2. ECONOMIC ACTIVITY RESULTS TABLE BUSINESS
3. Statement of Cash Flows BAD

✓ The financial report is posted on the Company's website at:
<https://amvibiotech.com/bao-cai-tai-chinh>





Amvi
Biotech Incorporation.

**VIET MY PHARMACEUTICAL AND MEDICAL
EQUIPMENT MANUFACTURING AND TRADING JOINT
STOCK COMPANY
LEGAL REPRESENTATIVE**

